Abstract 5710
Background
Merkel cell carcinoma (MCC) is a rare, aggressive tumour of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of various checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is currently the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC). Here, we report the Dutch real-world efficacy data of avelumab in patients with mMCC.
Methods
All mMCC patients from 4 tertiary referral centres in the Netherlands from December 2016 were analysed. Patients were included in this analysis if they had received avelumab for mMCC, regardless of other previous lines of therapy. Patient data were collected retrospectively and followed up prospectively after initiation of data collection. Primary endpoints were response rate (RR) and duration of response (DOR) , secondary endpoints were progression free survival (PFS), overall survival (OS) and toxicity. Toxicity was evaluated according to CTCAE version 5.0.
Results
Forty-six patients received avelumab, of which 37 patients were evaluable for response (9 had not reached response evaluation, 1 died due to comorbidity). In 22 (59.5%) patients avelumab was first-line treatment. Median follow up time was 7.8 (IQR 3.7-10.1) months. RR was 59.5% (n = 22) with 21.6% (n = 8) of patients having a complete radiological response. Median DOR was 6.3 (IQR 3.0-12.5) months and 15 (40.5%) patients had ongoing response at time of data analysis. Median PFS was 12.2 (95% CI 3.3-21.1) months, median OS was not yet reached. In subgroup analysis no differences were found for the presence of visceral metastases at baseline or previous lines of therapy. Five (13.2%) patients experienced grade 3 toxicity, of which 2 (4.3%) patients discontinued avelumab. No grade 4-5 toxicity were seen.
Conclusions
In the Netherlands treatment with avelumab is increasingly used in first- and second-line treatment for mMCC. In this real-world cohort, RR, DOR, PFS and toxicity results were in line with results from clinical trials and show relatively high, durable responses in patients with mMCC, unaffected by the presence of visceral metastases or previous lines of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract